20th week of 2011 patent applcation highlights part 37 |
Patent application number | Title | Published |
20110117123 | Multivalent Vaccine Composition With Mixed Carrier - The invention concerns a pharmaceutical composition for treating or preventing a certain number of infections caused by pathogenic agents such as bacteria, comprising as immunogen, one or several polyosides derived from one or several pathogenic agents. The polyosides are in the form of conjugates, coupled with a carrier protein. The composition contains at least two types of conjugates, each being at least characterised by a different protein carrier. | 2011-05-19 |
20110117124 | ENHANCEMENT OF TRANSGENE EXPRESSION FROM VIRAL-BASED VACCINE VECTORS BY EXPRESSION OF SUPPRESSORS OF THE TYPE I INTERFERON RESPONSE - Viral-based vectors are genetically engineered to express inhibitors of the anti-viral immune system (e.g. inhibitors of the type I interferon response) in order to enhance transgene expression. The transgenes may encode antigens or other therapeutic agents. | 2011-05-19 |
20110117125 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS - The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. | 2011-05-19 |
20110117126 | ATTENUATED PESTIVIRUS - The present invention relates to recombinant attenuated pestiviruses, in particular to recombinant attenuated CSFV, BVDV, or BDV, wherein said recombinant attenuated pestivirus does not produce a dimeric E | 2011-05-19 |
20110117127 | ANALYSIS OF DNA BY MEANS OF CAPILLARY ELECTROPHORESIS - The present invention relates to a method for detecting nucleic acids, wherein a sample to be analyzed for the presence of nucleic acids is separated by capillary electrophoresis. The conditions of sample injection and separation allow for an extremely high sensitivity of the method, which can be applied, e.g. for quality control purposes in the determination or the presence, quantity and/or size of genomic DNA contaminants in samples comprising proteins for therapy or vaccination. | 2011-05-19 |
20110117128 | Compositions that Include Hemagglutinin, Methods of Making and Methods of Use Thereof - Compositions comprise a flagellin component that is at least a portion of a flagellin, wherein the flagellin component includes at least one cysteine residue and whereby the flagellin component activates a Toll-like Receptor 5. Compositions can further include an antigen, such as an influenza antigen. The compositions are used to stimulate an immune response and a protective immune response in a subject. | 2011-05-19 |
20110117129 | Vaccine Against Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HP PRRS) - The present invention is related to methods and attenuated viral compositions for use in preventing and treating a high fever disease forms associated with porcine reproductive and respiratory syndrome (PRRS), such as highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS), a viral disease affecting swine. | 2011-05-19 |
20110117130 | Method of diagnosing and treating Ehrlichia - The present invention provides an isolated and purified heat shock protein 60 (Hsp60) peptide having the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to a vaccine against | 2011-05-19 |
20110117131 | Production of OspA for Lyme Disease Control - The present invention relates, generally, to the production of one or more OspA proteins in plant cells. Heterologous DNA comprising genes encoding one or more desired OspA protein(s) are introduced into plant cells. The one or more OspA protein(s) can be recombinantly-produced in the plant cells, optionally purified from the plant cells, and used as an oral vaccine to prevent the transmission of Lyme disease, particularly by animal vectors. The recombinantly-produced OspA protein(s) can be provided in oral and parenteral formulations. The present invention also relates to oral administration of OspA protein(s) to vaccinate against Lyme disease. The OspA protein(s) may be provided in a dosage form that is suitable for oral administration as a vaccine to prevent an animal from developing Lyme disease after exposure to a source of | 2011-05-19 |
20110117132 | MUTATED SALMONELLA TYPHI STRAIN AND USE THEREOF IN A VACCINE - The present invention relates to an attenuated | 2011-05-19 |
20110117133 | Novel Recombinant BCG Tuberculosis Vaccine Designed to Elicit Immune Responses to Mycobacterium Tuberculosis in all Physiological Stages of Infection and Disease - A vaccine against | 2011-05-19 |
20110117134 | Gene library of Brucella suis surface antigens - The invention relates to a bacterial antigen library of | 2011-05-19 |
20110117135 | Method of Forming Dendritic Cells from Embryonic Stem Cells - This invention relates to the culture of dendritic cells from human embryonic stem (ES) cells. Human ES cells are first cultured into hematopoietic cells by co-culture with stromal cells. The cells now differentiated into the hematopoietic lineage are then cultured with GM-CSF to create a culture of myeloid precursor cells. Culture of the myeloid precursor cells with the cytokines GM-CSF and IL-4 causes functional dendritic cells to be generated. The dendritic cells have a unique phenotype, as indicated by their combination of cell surface markers. | 2011-05-19 |
20110117136 | DEHYDROEPIANDROSTERONE PRODUCTION PROMOTER AND USE THEREOF - A new orally administerable DHEA production promoter is provided. A composition containing an extract of at least one selected from the group consisting of plants of Rosaceae | 2011-05-19 |
20110117137 | TAPASIN AUGMENTATION FOR ENHANCED IMMUNE RESPONSE - Tapasin (Tpn) is a member of the MHC Class I loading complex and functions to bridge the TAP peptide transporter to MHC Class I molecules. Metastatic human carcinomas express low levels of the antigen processing components (APCs) tapasin and TAP, and display few functional surface MHC Class I molecules. As a result, carcinomas are often unrecognizable by effector cytolytic T cells (CTLs). Tpn alone can enhance survival and immunity of mammals against tumors, but additionally, Tpn and TAP can be used together as components of immunotherapeutic vaccine protocols to eradicate tumors. | 2011-05-19 |
20110117138 | CHARGE-DYNAMIC POLYMERS AND DELIVERY OF ANIONIC COMPOUNDS - The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided. | 2011-05-19 |
20110117139 | FULLY SYNTHETIC ALBUMIN ANALOG - The present invention relates to a fully synthetic albumin analog, to a hemocompatible coating for medical devices containing the fully synthetic albumin analog, as well as to medical devices coated with the hemocompatible coating. The albumin analog preferably has two basic structures which are connected with one another via at least one bridging unit, the basic structures respectively having, in a geometrically defined manner, at least two bound joint regions to which at least one residue is covalently bound, wherein the basic structures are, respectively, a benzene carboxylic acid, and wherein the joint regions are formed via acid amide bonds, and wherein each residue, respectively, comprises a lipophilic region and a hydrophilic region. | 2011-05-19 |
20110117140 | Zinc Salt Compositions for the Prevention of Dermal and Mucosal Irritation - The present invention provides for compositions and methods that may offer protection from irritants as well as antimicrobial protection. Preferred embodiments of the invention include topical antimicrobial compositions that lack conventional antibiotics or preservatives, wherein the antimicrobial benefit is created by essential oils (or their active ingredients), emollient solvents and, in some instances, anti-inflammatory agents. | 2011-05-19 |
20110117141 | METHODS AND COMPOSITIONS COMPRISING NOVEL CATIONIC LIPIDS - Provided herein are novel cationic lipids, compositions comprising the cationic lipids, and methods of using the cationic lipids. In some claims, the cationic lipids have cytotoxic activity and can be used alone or in combination with a cytotoxic bioactive compound to kill a cell. In some of these claims, the cationic lipid enhances the cytotoxic activity of the cytotoxic bioactive compound. Methods for treating a subject afflicted with a disease or unwanted condition are provided, wherein the method comprises administering a delivery system comprising a novel cationic lipid to the subject. The invention further provides methods for making delivery systems comprising the novel cationic lipids of the invention. | 2011-05-19 |
20110117142 | METHOD FOR COATING TABLETS - The present invention relates to a polymeric composition for coating solid substrates (S) consisting of:
| 2011-05-19 |
20110117143 | TREATMENT OF CELIAC DISEASE WITH IgA - A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. | 2011-05-19 |
20110117144 | Topical cosmetic preparation containing elastogenesis inducing substances associated with a systemic absorption retardant - A cosmetic/dermatological topical preparation such as a cream or ointment or lotion containing elastogenesis inducing substances such as a dill extract or Ethocyn associated with a systemic absorption retardant such as a mixture of Benzyl Alcohol, Acetone and Isopropanol. Such a formulation achieves high local tissue concentration of the elastogenesis inducing substances in vicinity to the site of application, via minimization of systemic absorption of the elastogenesis inducing substances and at the same time via promotion of their intradermal absorption across the epidermal barrier. As a result of the use of such formulation an increased elastogenesis activity is expected to occur in the dermis, ultimately resulting in the neo-formation of an elastin network in the adult skin. The use of other percutaneous chemical transdermal enhancers such as liposomes and cyclodextrins to be added to the cosmetical preparation or the use of physical penetration enhancers such as Micro-Dermabrasion or Iontophoresis, are also disclosed, to favor penetration of the cosmetic preparation into the skin. | 2011-05-19 |
20110117145 | COSMETIC - Provided is a cosmetic including silicone microparticles, in which the silicone microparticles include 100 parts by mass of silicone elastomer spherical microparticles having a volume average particle diameter within a range from 0.1 to 100 μm, and 0.5 to 25 parts by mass of a polyorganosilsesquioxane that coats a surface of the silicone elastomer spherical microparticles, and the silicone elastomer is capable of absorbing not less than 30 parts by mass of at least one oily substance selected from the group consisting of sebum, hydrocarbon oils and ester oils per 100 parts by mass of the silicone elastomer. Even if containing an unctuous agent, the cosmetic exhibits favorable feelings upon use, with no spreading difficulties, stickiness, greasiness, oily film feeling, or the like, and is also capable of suppressing problems caused by sebum, namely, changes in the makeup cosmetic properties of the cosmetic, changes in the color of the cosmetic, increased shine, and the like. | 2011-05-19 |
20110117146 | COSMETIC - Provided is a cosmetic including silicone microparticles, in which the silicone microparticles include 100 parts by mass of silicone elastomer spherical microparticles having a volume average particle diameter within a range from 0.1 to 100 μm, and 0.5 to 25 parts by mass of a polyorganosilsesquioxane that coats the surface of the silicone elastomer spherical microparticles, and the silicone elastomer is capable of absorbing not less than 200 parts by mass of a polymethylsiloxane having a viscosity at 25° C. of not more than 10 mm | 2011-05-19 |
20110117147 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION - The invention relates to a cooling sensation agent composition with a prolonged cool sensation effect comprising at least one compound selected from Formula (1) wherein each of A and B is a hydrogen atom or a hydrocarbon group which may have one or more substituents, in which A and B are not hydrogen atoms simultaneously, and the total number of carbon atoms in A and B is in the range of 6 to 18; and Formulae (2) to (4) wherein R1, R2, and R3 each represent a residue of an alcohol selected from 1-menthol, 1-isopulegol, 3-(1-menthoxy)propan-1,2-diol, 2-(1-menthoxy)ethan-1-ol, 3-(1-menthoxy)propan-1-ol, 2-methyl-3-(1-menthoxy)propan-1,2-diol and para-menthan-3,8-diol), and R4 represents a residue of a branched or straight-chain, cyclic or linear, or saturated or unsaturated alcohol having 6 to 18 carbon atoms that may have one or more aromatic rings that may have a condensed ring and substituent groups such as hydroxyl and ether groups; and R6 represents a hydrocarbon group having 11 to 19 carbon atoms that may be branched and contain one or more unsaturated bonds. The invention also relates to a sensory stimulation agent composition comprising the cooling sensation agent composition; a flavor or fragrance composition, a beverage or food product, a perfume or cosmetic product, a toiletry product, a daily utensil product or grocery, a fiber, a fiber product, a cloth or a medicine comprising the cooling sensation agent composition or the sensory stimulation agent composition; a production method thereof; a cooling processing method of a fiber, fiber product or a cloth, comprising compounding the cooling sensation agent composition or the sensory stimulation agent composition; and new compounds. | 2011-05-19 |
20110117148 | WHITENED EXINE SHELLS - A whitened exine shell having a degree of whiteness (L*) of greater than 65 measured under D 65 illumination. The shell can be used as a delivery vehicle for an active substance, or as an antioxidant. It can be used in a method of surgery, therapy or diagnosis. The invention provides a formulation containing the whitened exine shell together with an active substance; and a method for preparing the shell by isolating an exine shell from a naturally occurring spore under treatment conditions which do not include acetolysis, and treating the isolated shell or a precursor thereof with a bleaching composition. | 2011-05-19 |
20110117149 | INORGANIC NANOTUBES - Discloses are stabilized calcium pyrophosphate nanotubes, a process for making calcium pyrophosphate nanotubes comprising agitating at less than 2 OkHz an aqueous suspension of a calcium and a phosphate for a time sufficient to precipitate said inorganic calcium pyrophosphate nanotubes, and uses thereof. | 2011-05-19 |
20110117150 | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject - A device, a system, or a method is described for treating a disease or condition of one or more joints of articulating bone in a mammalian subject. A device is described which includes one or more substrates configured to contact one or more body contours at one or more joints of articulating bone of a mammalian subject; and an applicator supported by the one or more substrates and configured to inject one or more medicaments to one or more joint tissues of the mammalian subject. | 2011-05-19 |
20110117151 | Device,system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject - A device, a system, or a method is described for treating a disease or a condition of one or more joints of articulating bone in a mammalian subject. The device provides one or more medicaments to one or more joints of the mammalian subject. A device is described that includes one or more substrates configured to contact one or more body contours in proximity to one or more joints of articulating bone of a mammalian subject; one or more sensors configured to monitor movement of the one or more body contours; and one or more applicators supported by the one or more substrates and configured to respond to the movement of the one or more body contours by injecting one or more medicaments to the one or more joint tissues of the mammalian subject. | 2011-05-19 |
20110117152 | SILICONE RUBBER EXHIBITING EFFECTIVE ANTIMICROBIAL ACTIVITY - A silicone rubber exhibiting antimicrobial efficacy contains: a) at least one silicone rubber derived from a curable silicone rubber-forming composition; b) at least one silver-containing antimicrobial agent incorporated in silicone rubber (a) in X weight percent amount; and, c) at least one carboxylic acid incorporated in silicone rubber (a) in Y weight percent amount, silver-containing antimicrobial agent (b) when incorporated by itself in silicone rubber (a) in an amount of X+Y weight percent therein and carboxylic acid (c) when incorporated by itself in silicone rubber (a) in an amount of X+Y weight percent therein imparting no significant antimicrobial activity to silicone rubber (a) but in the combination therein of up to X weight percent silver-containing antimicrobial agent (b) and up to Y weight percent carboxylic acid (c) imparting significant antimicrobial activity to silicone rubber (a), such activity being exhibited at the interface of an exposed surface of silicone rubber (a) and a microbe-populated aqueous material in contact therewith. | 2011-05-19 |
20110117153 | SPINOSYN BAIT FORMULATIONS FOR THE CONTROL OF COCKROACHES AND METHODS OF USING THE SAME - The present invention relates to a pest control product in an ingestible form, comprising at least one active ingredient in need of masking, e.g., spinosyn or derivative or salt thereof, and at least one masking agent, wherein said product achieves mortality against cockroaches. The present invention also relates to a pest control product in an ingestible form, wherein at least one spinosyn is microencapsulated, and wherein said product achieves mortality against cockroaches. The present invention also relates to a method for controlling cockroach populations by administering the pest control product. | 2011-05-19 |
20110117154 | USE OF RIFALAZIL TO TREAT COLONIC DISORDERS - Methods for treating bacterial infections in the colon, and colonic disorders caused by bacterial infection, using a poorly absorbable form of Rifalazil, are described. Compositions for oral administration, and colonic delivery, of a non- micro-granulated Rifalazil formulation, are also described. Rifalazil is delivered in a form which is poorly absorbed in the gut after oral dosing, and the vast majority of the orally-dosed Rifalazil is not absorbed in the gut. Accordingly, the antibacterial potency in the colonic flora will be enhanced, while absorption and systemic circulation will be reduced, thus reducing potential adverse events. | 2011-05-19 |
20110117155 | PESTICIDE STRIPS FOR CONTROL OF MITES IN HONEYBEES - Pesticide strips used to control parasitic mites in honeybees. The pesticide strips are designed to have a lifetime or period of existence, after which the strip no longer exists in its original form. The strip breaks down, such as by disintegration, dissolving, decomposition, being eaten or carrier away, or otherwise degrading over time, so that at the end of the recommended lifetime, the strip is no longer in its original form. In most embodiments, at least 50% of the strip is no longer present, and in other embodiments at least 75% of the strip is no longer present. Preferably, at the end of the recommended lifetime, the strip no longer exists, at least the body of the strip that included the active ingredient. With this design, the strip does not provide extended low-dose pesticide that can be detrimental in treating the mites. | 2011-05-19 |
20110117156 | COMPOSITIONS AND ARTICLES CONTAINING AN ACTIVE LIQUID IN A POLYMERIC MATRIX AND METHODS OF MAKING AND USING THE SAME - Described herein are compositions and articles containing a polymeric matrix and an active liquid intermixed with at least a portion of the polymeric matrix. Methods of making and using the compositions and articles are also described herein. | 2011-05-19 |
20110117157 | METHOD OF MANUFACTURE OF SUSTAINED-RELEASE FORMULATION COMPOSITION - The present invention offers a method of manufacture of sustained-release formulation composition which includes a step of spray drying a composition that contains (1) an active ingredient, (2) a resin ingredient, and (3) a solvent, using a spray dryer and controlling the exit temperature of the spray dryer, wherein solvent content in the composition after spray drying is 5 mass % or less, and the composition after the aforementioned spray drying does not substantially contain decomposed matter of the aforementioned active ingredient. | 2011-05-19 |
20110117158 | INHIBITION AND DISPERSION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-TRIAZOLE DERIVATIVES - Disclosure is provided for imidazole-triazole derivative compounds that prevent, remove and/or inhibit the formation of biofilms, compositions comprising these compounds, devices comprising these compounds, and methods of using the same. | 2011-05-19 |
20110117159 | INHIBITION OF JAK2 AS A TREATMENT OF PULMONARY ARTERIAL HYPERTENSION - The present invention relates to a method of treating pulmonary arterial hypertension by administering a therapeutically effective amount of a selective JAK2 inhibitor to a patient in need thereof. | 2011-05-19 |
20110117160 | ANTAGONISTIC PROPERTIES OF REEF FISH MICROFLORA - The present invention provides methods for preventing biofilm formation on a surface. The present invention also relates to anti-biofilm forming agents, to methods of producing and using them, and to anti-fouling coatings produced therefrom. | 2011-05-19 |
20110117161 | BIOLOGICALLY ABSORBABLE COATINGS FOR IMPLANTABLE DEVICES AND METHODS FOR FABRICATING THE SAME - Coatings for an implantable medical device and a method of fabricating thereof are disclosed, the coatings comprising a biologically degradable, biologically erodable, and/or biologically resorbable ABA or AB block copolymer. A biologically active agent can be conjugated to the block copolymer. | 2011-05-19 |
20110117162 | Isolated Renal Cells and Uses Thereof - The invention is directed to isolated renal cells, including tubular and erythropoietin (EPO)-producing kidney cell populations, and methods of isolating and culturing the same, as well as methods of treating a subject in need with the cell populations. | 2011-05-19 |
20110117163 | BIOACTIVE COATING FOR AN IMPLANTABLE DEVICE OR BIOPROSTHESIS - For an implantable device intended for use in the human body an in-vivo colonization with autologous cells is often desired. The devices, especially prosthetic devices like implant tissues, grafts, shunts, vessels, organs or a part of organs are commonly derived from animal or human origin and comprise a collagen-based tissue matrix. The invention proposes a coating deposited on a surface of the device and comprising the matrix protein CCN1 as an extracellular matrix-associated protein mediating cell adhesion or cell migration. | 2011-05-19 |
20110117164 | Use of Additive Sites to Control Nitric Oxide Release from Nitric Oxide Donors Contained within Polymers - A method for increasing, prolonging, and/or controlling the release rates of nitric oxide (NO) from polymeric materials containing NO adducts. Such NO-containing polymeric materials may find use in devices such as blood contacting devices, and biocompatible devices utilizing the same. The method and device utilizes anionic site additives, acidic site additives and/or acidic producing site additives in a polymer that contains NO-adducts to generate higher fluxes of NO to exceed NO threshold levels desirable to substantially prevent and/or minimize reactions such as platelet activation or adhesion. | 2011-05-19 |
20110117165 | IMPLANTABLE BONE GRAFT MATERIALS - Compositions and methods are provided for promoting bone growth. An implantable bone graft material is provided comprising a resorbable ceramic and a resorbable polymer, wherein the polymer comprises a covalently attached BMP binding peptide. In addition, an implantable bone graft material is provided consisting essentially of a resorbable β-TCP and a resorbable polymer, wherein the β-TCP has a total porosity of about 50% or greater and wherein the β-TCP has a particle size ranging from about 100 micron to about 300 micron. The implantable bone graft materials are useful for promoting bone growth in a subject. | 2011-05-19 |
20110117166 | IMPLANTABLE BONE GRAFT MATERIALS - Compositions and methods are provided for promoting bone growth. An implantable bone graft material is provided comprising a resorbable ceramic and a resorbable polymer, wherein the polymer comprises a covalently attached BMP binding peptide. In addition, an implantable bone graft material is provided consisting essentially of a resorbable β-TCP and a resorbable polymer, wherein the β-TCP has a total porosity of about 50% or greater and wherein the β-TCP has a particle size ranging from about 100 micron to about 300 micron. The implantable bone graft materials are useful for promoting bone growth in a subject. | 2011-05-19 |
20110117167 | METHODS AND COMPOSITIONS FOR SOFT TISSUE REPAIR - Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide. | 2011-05-19 |
20110117168 | METHODS AND COMPOSITIONS FOR SOFT TISSUE REPAIR - Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide. | 2011-05-19 |
20110117169 | METHODS AND COMPOSITIONS FOR CAPTURE OF CELLS - Compositions and methods are provided for capturing cells. Cell binding peptides are provided that bind to one or more of stem cells, fibroblasts, or endothelial cells. In the methods, a sample containing cells is contacted with a cell binding peptide attached to a substrate, and the cells present in the sample are captured onto the substrate through binding to the cell binding peptide. | 2011-05-19 |
20110117170 | Controlled Release of Growth Factors and Signaling Molecules for Promoting Angiogenesis - The present invention comprises compositions, methods, and devices for delivering angiogenic factors and signaling molecules to a target tissue, and controlling the release of these factors and signaling molecules to spatially and temporally restrict their release and dissemination, for the purposed promoting angiogenesis in target tissues. | 2011-05-19 |
20110117171 | IMPLANTABLE BONE GRAFT MATERIALS - Compositions and methods are provided for promoting bone growth. An implantable bone graft material is provided comprising a resorbable ceramic and a resorbable polymer, wherein the polymer comprises a covalently attached stem cell binding peptide. The implantable bone graft materials are useful for promoting bone growth in a subject. | 2011-05-19 |
20110117172 | CROSS-LINKED POLYMER MATRIX, IN PARTICULAR FOR ADMINISTERING ACTIVE SUBSTANCES - The subject is cross-linked polymer matrices, which are used as active substance supports and can be applied locally or parenterally in human or animal bodies. The cross-linked polymer matrices are in particular self-dissolving cross-linked polymer matrices. | 2011-05-19 |
20110117173 | POWDERED CHEWING GUM COMPOSITIONS, THE USE THEREOF AND A METHOD OF PREPARING SUCH COMPOSITIONS - The present invention relates to a powdered chewing gum composition, which contains over 50% w/w chewing gum base and wherein at least 95% w/w of the particles of the composition have a particle size of less than 1200 micron in diameter. The present invention also relates to the use of said powdered chewing gum composition. The present invention also relates to a chewing gum comprising a) a core component, and b) one or more layers comprising the composition of the present invention. The present invention further relates to a method for production of said chewing gum comprising the steps of: (a) providing a core composition; and (b) coating of the core composition with a powdered chewing gum composition by use of a panning process; and optionally (c) coating the outer intermediate layer with an outer finishing layer by use of a panning process. | 2011-05-19 |
20110117174 | ADHESIVE ARTICLE CONTAINING COLORANT AND/OR ACTIVE AGENT - The invention relates to adhesive articles containing at least one colorant and/or at least one active agent as well as to methods of using such articles on mucosis or keratin materials to achieve a desired result or benefit and to methods of making such adhesive articles. | 2011-05-19 |
20110117175 | SWEET ANALGESIC FOR USE IN MEDICAL PROCEDURES OR TREATMENTS - Sweet analgesics and compositions comprising a sweet analgesic and a delivery vehicle for reducing pain or discomfort associated with a medical procedure or treatment are disclosed. The sweet analgesic is administered or delivered to the intra-oral cavity of the patient prior to or during the medical procedure or treatment to increase the comfort of the patient. The sweet analgesic can be applied to a dental roll or pad and the roll or pad can be inserted between the cheek and gum of the patient to allow for the release of the sweet analgesic during the medical procedure or treatment. The dental roll or pad can be replaced as necessary to maintain the release of the sweet analgesic into the intra-oral cavity of the patient during the medical procedure or treatment. | 2011-05-19 |
20110117176 | HYDROPHILIC POLYPROPYLENE FIBERS HAVING ANTIMICROBIAL ACTIVITY - Polypropylene fibers and devices that include a fatty acid monoglyceride added to the polypropylene as a melt additive are described. A hydrophilic enhancer material can be advantageously added to the polypropylene as a melt additive to enhance the hydrophilicity of the fibers and devices. An antimicrobial enhancer material can be added to the fibers to enhance the antimicrobial activity. | 2011-05-19 |
20110117177 | Method for producing a multilayer compound on a CIP-capable coating installation and use of the multilayer compound produced by said method for transdermal application or the application in body cavities - Methods for producing a mono- or multilayer composite are provided in which one or several layers are applied onto a carrier material by coating, the coated mono- or multilayer composite is dried and rolled up, and the installation is subsequently cleaned. The air circuit in the drying oven is entirely set to fresh air supply, and the drying oven is configured to be cleaned in a controlled manner. All components of the drying oven that come into contact with the product do not have to be removed during cleaning, but can be cleaned-in-place using technology integrated into the drying oven. The drying oven Outer housing is designed so that it can be lifted upwardly. All assembly parts in the drying oven interior are designed to eliminate disassembling for cleaning purposes. Transport rollers within the drying oven are designed as hollow shafts and provided with spraying nozzles. | 2011-05-19 |
20110117178 | WOUND DRESSING COMPRISING A HYDROGEL MATRIX - The present invention relates to a multilayered wound dressing particularly for wound treatment in the granulation and epithelization phase. The wound dressing comprises
| 2011-05-19 |
20110117179 | COMPOSITIONS COMPRISING ELEMENTAL METALS AND USES THEREFOR - The invention provides compositions and devices for altering biological field effects and methods for their use in therapeutic and agricultural applications. In particular, the invention provides compositions including one or more elemental metals coated with one or more non-conducting or semi-conducting materials and methods for their application to animals (including humans) and/or plants. | 2011-05-19 |
20110117180 | VEGETARIAN MICROCAPSULES - Disclosed are microcapsules with shells that are not animal by-products and methods for preparing and using such microcapsules. | 2011-05-19 |
20110117181 | TREATING HEPATITIS C VIRUS INFECTION WITH OVER-EXPRESSION OF MICRORNA-196 - The present invention is directed to methods of treating cells infected with HCV and mammals suffering from HCV infection by transfecting the infected cells with miRNA-196 mimic. miRNA-196 mimic significantly down-regulates Bach1 protein and HCV gene expression, while also up-regulating HMOX1 gene expression. miRNA-196 binds with the 3′-UTR of Bach1 mRNA to reduce the expression of Bach1. As such, miRNA-196 can play an important role in the regulation of HCV replication and HMOX1/Bach1 expression in hepatocytes. The present invention also provides a formulation for the treatment of cells expressing HCV comprising a therapeutically effective amount of miRNA-196 such that Bach1 and HCV gene expression are down-regulated while HMOX1 expression is increased. The formulations are adapted to enable the transfection of miRNA-196 mimic into hepatocytes expressing HCV proteins. | 2011-05-19 |
20110117182 | COMBINATION OF DAPSONE WITH OTHER ANTI-ACNE AGENTS - A composition suitable for topical application that contains at least two active ingredients, one of these being dapsone and one selected from the group consisting of adapalene, tazarotene and treinion for the effective treatment of acne and other dermatological conditions. | 2011-05-19 |
20110117183 | Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1 Expressing Neuroendocrine Tumors - A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene. | 2011-05-19 |
20110117184 | Compositions for mucosal delivery of agents - Compositions and methods for mucosal delivery of agents are provided. The compositions are intended for administration to mucosal surface, such as oral, gastrointestinal and nasal mucosa. The compositions provided contain one or more mucoadhesive proteins and an agent to be delivered. Methods for delivery of agents using the compositions provided herein are also provided. | 2011-05-19 |
20110117185 | METHODS FOR TREATING OR PREVENTING HEART DAMAGE WITH INTEGRIN-LINKED KINASE (ILK) COMPOSITIONS - The present invention generally provides methods for administering a composition having an ILK-based protein or peptide having a sequence that is at least 90% homologous to wild-type human integrin-linked kinase (ILK) protein for use in treating or administering to cardiac cells in vitro or in vivo. The ILK-based protein or peptide may further have a mutation or substitution at a position corresponding to amino acid position 211 of wild-type human ILK replacing the arginine (R) with an alanine (A). The present invention further provides compositions having polynucleotides encoding such proteins or peptides. Various vectors, delivery reagents and the like are also provided for use in delivering the compositions to cells. The compositions administered to cells in vitro or in vivo according to present methods may be used to treat, prevent, etc., heart failure, ischemic disease, cardiomyopathy, etc. | 2011-05-19 |
20110117186 | INTRAVENOUS INFUSION OF CURCUMIN AND A CALCIUM CHANNEL BLOCKER - Compositions and methods for treating systemic diseases by intravenous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly a calcium channel blocker to human subjects with neoplastic and neurodegenerative diseases are disclosed herein. The diseases are treated by prolonged administration of sub-optimal doses of liposomal curcumin or polymeric nanocurcumin or the sustained release curcumin from PLGA nanocurcumin at dosages below systemic hemolytic thresholds concomitantly with or without calcium channel blockers. | 2011-05-19 |
20110117187 | TOPICAL COMPOSITIONS AND METHODS FOR EPITHELIAL-RELATED CONDITIONS - The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditions | 2011-05-19 |
20110117188 | Group of Nucleic Acid Fragments for Prevention of HIV Infection or AIDS and the Usage Thereof - The invention provides a group of nucleic acid fragments, shown in the sequence listing, for prevention of HIV infection or AIDS and the usage thereof. In the invention, a series of RNA fragments, which are highly homogenous to all the published HIV gene sequences, were obtained by homology compare. The double-stranded RNA (dsRNA) derived from these fragments can effectively inhibit the expression of the HIV genes. The RNA transcribed by plasmid, also can suppress the expression of the HIV in the cell. After the adenovirus or associated virus which carry DNA corresponding above RNA infect the cell, the transcription dsRNA can inhibit the expression of the HIV genes. | 2011-05-19 |
20110117189 | OPHTHALMIC COMPOSITIONS FOR TREATING PATHOLOGIES OF THE POSTERIOR SEGMENT OF THE EYE - New compositions for ophthalmic use for the prevention and therapy of pathologies of the posterior segment of the eye. These compositions utilize xanthan gum as an active principle carrier, and can be advantageously administered as liquid-gel eye drops on the surface of the eye and optionally used in combination with other therapies for the treatment of the same pathologies. | 2011-05-19 |
20110117190 | Pharmaceutical Formulations - The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection moulding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form. | 2011-05-19 |
20110117191 | MIXTURE OF SUBSTANCES ON THE BASIS OF A MIXTURE OF ESSENTIAL OILS AND USE - The invention relates to a substance mixture on the basis of a mixture of essential oils, wherein the oil mixture contains juniper oil and turpentine oil, in particular turpentine oil of the duster pine type or substantially comprises them, and wherein the substance mixture preferably furthermore contains a liquid and/or dissolved active ingredient or a mixture of a plurality thereof and/or an active ingredient in powder form or a mixture of a plurality thereof. | 2011-05-19 |
20110117192 | CARBIDOPA/LIPODOPA GASTRORETENTIVE DRUG DELIVERY - A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer. | 2011-05-19 |
20110117193 | ANTIRETROVIRAL DRUG FORMULATIONS FOR TREATMENT OF CHILDREN EXPOSED TO HIV/AIDS - The present disclosure provides fast disintegrating formulations for the treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) in patients such as neonatal, perinatal and pediatric children. Neonatal and perinatal formulations provide for the prevention or reduction of incidence of mother to child transmission of HIV. Also provided are formulations and methods for treating pediatric children having HIV/AIDS. The orally administered fast disintegrating formulations are in granule and tablet form and are specially formulation for children to increase adherence to treatment protocols. | 2011-05-19 |
20110117194 | PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER - The present invention provides a pharmaceutical formulation containing an angiotensin-II receptor blocker and a release-control material as a pharmacologically active ingredient and a pharmaceutical formulation comprising an immediate-release compartment and an extended-release compartment. The immediate-release compartment contains an agent as a pharmacologically active ingredient for preventing and inhibiting hepatitis and the extended-release compartment has an angiotensin-II receptor blocker as a pharmacologically active ingredient. The formulation of the present invention maximizes the effectiveness on pharmacologically and clinically lowering blood pressure and preventing complications when taking the formulation, helps to avoid interaction with a drug which is metabolized by the same enzyme in the liver, and prevents and inhibits the incidence of drug-induced hepatitis which is caused by drug administration for a long time. | 2011-05-19 |
20110117195 | METHOD FOR IMPROVING MYOCARDIAL INFARCTION BY INTRAMYOCARDIAL OR TRANSENDOCARDIAL INJECTION OF PEPTIDE NANOFIBERS - A method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers is disclosed. The method firstly provides a pharmaceutical composition having a biologically compatible peptide hydrogel formed by a plurality of self-assembling peptide nanofibers and selectively having at least one type of autologous stem cells mixed with the self-assembling peptide nanofibers, and then the pharmaceutical composition is administered to an entire infarcted area of myocardium tissue with myocardial infarction by intramyocardial or transendocardial injection. Thus, adverse cardiac remodeling and dysfunction after acute infraction can be attenuated, while the therapeutic myocardial angiogenesis, the myocardial capillary density and potential myogenesis can be enhanced. | 2011-05-19 |
20110117196 | Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects - The invention provides a novel solid pharmaceutical dosage form which includes an opiate, an opiate antagonist admixed with the analgetic (opiate agonist) and an amount of a hydrocolloid containing excipient which is effective to form a non-injectable slurry when the dosage form is contacted with water. In addition the dosage form contains pure naloxone in enteric coated form which is designed to release in the colon to prevent or relieve constipation. Thus the formulation, because of the enteric coated naloxone and the hydrocolloid excipient(s), has reduced side effects as compared with formulations which do not contain these features. | 2011-05-19 |
20110117197 | SUSTAINED-RELEASE DRUG CARRIER COMPOSITION - The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof. | 2011-05-19 |
20110117198 | COMPOSITIONS OF SEMI-INTERPENETRATING POLYMER NETWORK - Novel compositions consisting of semi-interpenetrating network of cross-linked water soluble derivatives of basic polysaccharides and a non-cross-linked component, which is an anionic polysaccharide are provided. Methods for the production of such compositions are also disclosed. Preferably the basic polysaccharide is chitosan or a derivative thereof and the anionic polysaccharide is hyaluronic acid. The compositions can be formed into gels or films, for example, and thus find use in a wide range of medical applications in the fields of dermatology, plastic surgery, urology and orthopaedics. | 2011-05-19 |
20110117199 | FOAMY BIOMATERIAL FOR BIOLOGICAL TISSUE REPAIR - A kit for producing a foamed biocompatible material includes a container configured to sustain a high pressure, and a tissue-repair composition placed in the container. The composition contains a biocompatible material, a liquid carrier, and a gas. The container has an internal pressure of greater than 1 atm and less than 250 atm, and includes a valve and a nuzzle for releasing from the nuzzle a foam formed of the composition upon opening the valve. Methods of producing and applying the biocompatible material are also disclosed. | 2011-05-19 |
20110117200 | RASAGILINE MESYLATE PARTICLES AND PROCESS FOR THE PREPARATION THEREOF - Provided herein is rasagiline mesylate having a 90 volume-percent of the particles (D | 2011-05-19 |
20110117201 | COMPOSITION FOR TREATMENT OF WATER - The invention relates to a composition for treatment of water comprising rice husk ash and at least one bactericidal agent bonded to the rice husk ash. The bactericidal agent bonded to the rice husk ash is preferably silver and more particularly the bactericidal agent is nano silver. The invention also relates to a method of water purification using a composition comprising rice husk ash and at least one bactericidal agent bonded to the rice husk ash. | 2011-05-19 |
20110117202 | UP AND DOWN CONVERSION SYSTEMS FOR PRODUCTION OF EMITTED LIGHT FROM VARIOUS ENERGY SOURCES INCLUDING RADIO FREQUENCY, MICROWAVE ENERGY AND MAGNETIC INDUCTION SOURCES FOR UPCONVERSION - Methods and systems for producing a change in a medium. A first method and system (1) place in a vicinity of the medium at least one upconverter including a gas for plasma ignition, with the upconverter being configured, upon exposure to initiation energy, to generate light for emission into the medium, and (2) apply the initiation energy from an energy source including the first wavelength λ | 2011-05-19 |
20110117203 | PHARMACEUTICAL COMPOSITION CONTAINING WATER SOLUBLE DRUG - The present invention is directed to a process of preparing beads coated with a water soluble drug for incorporation into a pharmaceutical composition comprising: (a) preparing a supersaturated drug solution containing a desired amount of drug, which is completely saturated at a first temperature but which is supersaturated at a second temperature which is below the first temperature; and (b) coating inert beads with the drug solution, said drug solution being maintained at or below the first temperature but above the second temperature, and said beads maintained at a second temperature, wherein the second temperature is less than the first temperature and wherein the solution containing the drug is supersaturated at the second temperature, as well as to the pharmaceutical compositions containing same. | 2011-05-19 |
20110117204 | IMMUNOLOGICALLY ACTIVE COMPOSITIONS - This invention provides a microparticle carrier system comprising of one or more proteins, peptides, nucleic acids, carbohydrates, lipids or other bioactive substances with or without targeting molecules attached. In addition, the invention also provides immune modulatory compositions and methods of eliciting protective immune responses both in uninfected and infected hosts as well as the induction of immune tolerance. | 2011-05-19 |
20110117205 | ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF AQUEOUS SUSPENSION FOR MODIFIED RELEASE OF ACTIVE PRINCIPLE(S) - The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s). | 2011-05-19 |
20110117206 | PHOSPHOPEPTIDES AND USE OF THE SAME - The present application relates to methods of providing thermodynamically stable calcium phosphate nanoclusters and uses thereof. | 2011-05-19 |
20110117207 | USE OF EGGSHELL MEMBRANE FORMULATIONS TO ALLEVIATE JOINT PAIN - A method to treat and alleviate symptoms of joint pain in an individual is accomplished by administering a therapeutic amount of fowl eggshell membrane or processed eggshell membrane preparations in synergistic combination with other active constituents in an oral dosage form. | 2011-05-19 |
20110117208 | CHRONIC WOUND TREATMENT - The invention provides the use of an unbound polyphosphate to promote chronic wound healing, in which the polyphosphate has at least 3 phosphate units. Also provided are a method of treatment and a pharmaceutical composition, both based on the use of the polyphosphate. | 2011-05-19 |
20110117209 | COMPOSITION FOR DISINFECTION AND DECONTAMINATION OF BODIES CONTAMINATED BY PRIONS AND CONVENTIONAL TRANSMISSIBLE AGENTS - The invention relates to a composition for the simultaneous disinfection and decontamination of bodies contaminated by CTAs such as bacteria, yeasts, mould spores, viruses or others, and NCTAs such as prions. According to the invention, the composition includes a hydrogen peroxide solution and an aqueous solution of copper or a derivative thereof such as copper salts, and at least one anionic salified surfactant compound inhibiting the decomposition of hydrogen peroxide in the presence of copper. Said composition can be prepared extemporaneously from a mixture of an aqueous copper solution and of an aqueous hydrogen peroxide solution. The invention further relates to an aqueous copper solution and to an aqueous hydrogen peroxide solution to be mixed together. | 2011-05-19 |
20110117210 | Therapeutic treatment of human cancers using simple salts of zinc - The present invention is a non-topical method of therapeutically treating human cancer patients which comprises an administration of an anti-cancer medicament comprising at least one simple organic or inorganic salt of zinc in at least a minimally effective concentration to suppress malignant tumor growth and induce tumor regression in-vivo. Administration can be performed by oral, parenteral, and/or body cavity routings; and the therapeutic treatment method is effective for the treatment of a diverse range of primary human cancers and metastatic diseases. | 2011-05-19 |
20110117211 | Method of Treating or Preventing Tissue Deterioration, Injury or Damage Due to Disease of Mucosa - An immunomodulatory compound is utilized to treat mucosa disease. | 2011-05-19 |
20110117212 | THERAPEUTIC COMBINATION COMPRISING AN AURORA KINASE INHIBITOR AND AN ANTINEOPLASTIC AGENT - The present invention provides a therapeutic combination comprising (a) compound 1 of formula (A) as set forth in the specification and (b) one or more antineoplastic agents selected from the group consisting of platinum derivatives, antimetabolite agents, topoisomerase I inhibitors and antimicrotubule agents, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof. | 2011-05-19 |
20110117213 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM - The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen. | 2011-05-19 |
20110117214 | CYCLOHEXYL UREA MODULATORS OF D2 RECEPTORS AND/OR D3 RECEPTORS - The present invention relates to new cyclohexyl urea modulators of D2 receptors and/or modulators of D3 receptors, pharmaceutical compositions thereof, and methods of use thereof. | 2011-05-19 |
20110117215 | Microsatellite Markers of Schizophrenia - The invention includes method of determining if a subject is at risk for developing schizophrenia (SZ), schizotypal personality disorder (SPD), or schizoaffective disorder (SD). | 2011-05-19 |
20110117216 | ANTI-TUMOURAL EFFECTS OF CANNABINOID COMBINATIONS - The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). | 2011-05-19 |
20110117217 | METHOD OF USING GUAVA EXTRACT - A method of using guava extract is disclosed that includes administering guava extract to a mammal to inhibit, prevent or alleviate at least one of a headache, nausea, dry mouth, lack of appetite, shakiness, and fatigue. A composition is also disclosed that includes a pharmaceutically acceptable carrier and guava extract. | 2011-05-19 |
20110117218 | composition and uses for influencing hair growth - The invention describes a combination of at least one aromatase inhibitor selected from the group of chemical-synthetic aromatase inhibitors and aromatase inhibition exhibiting extracts of soya beans and rapeseed, respectively, and at least one plant extract that contains one or more active ingredient substance(s) extracted from the plant, which is(are) selected from the group of 5α reductase type I and/or type II inhibitors and androgen receptor blockers, said combination being contained for example in a composition and having special properties for influencing hair growth. Uses of this combination are also described. | 2011-05-19 |
20110117219 | HAIR TREATMENT PRODUCT AND HAIR AFTER-TREATMENT PRODUCT CONTAINING ETHER GUANIDINES AS ACTIVE SUBSTANCES, FOR PROTECTING FROM DAMAGE CAUSED BY CHEMICAL TREATMENT AND FOR REPAIRING ALREADY DAMAGED HAIR - The invention relates to ether guanidines of the general formulae (I) | 2011-05-19 |
20110117220 | PREPARATION METHOD OF PLANT EXTRACT USING HIGH PRESSURE-ENZYMATIC DECOMPOSITION TECHNIQUE AND THE COSMETIC COMPOSITION CONTAINING THE EXTRACT - The present invention relates to a method of preparing a plant extract using a high-pressure enzymatic decomposition technique (HPED technique) and to a cosmetic composition containing the prepared plant extract as an active ingredient. The plant extract prepared using the high-pressure enzymatic decomposition technique developed according to the present invention contains various kinds and large amounts of effective components compared to extracts prepared using other extraction techniques, such that the effects of the effective components can be maximized. | 2011-05-19 |
20110117221 | STABILIZED ANTHOCYANIN COMPOSITIONS - The invention describes stabile anthocyanin compositions, methods to prepare such compositions and also methods of use of such compositions to treat various afflictions. The present invention describes unique compositions of an anthocyanin and a stabilizing compound such that the combination of the two components provides that the anthocyanin does not readily undergo degradation, such as oxidation, pH instability, etc. | 2011-05-19 |
20110117222 | Pharmaceutical Compositions for the Treatment of Warts - The present invention relates to pharmaceutical compositions for the treatment, and especially topical treatment, of warts and the use thereof for the treatment of warts. Specifically, the present invention relates to pharmaceutical compositions for the treatment of warts, comprising: a) 0.1 to 10 weight % dimethicone; b) 5 to 25 weight % of one or more vegetable oils; c) one or more pharmaceutically acceptable excipients and/or carriers; d) 2 to 6 weight % urea; and e) water up to 100 weight %. | 2011-05-19 |